Catalyst Pharmaceuticals (NASDAQ:CPRX) Stock Rating Lowered by Zacks Research

Catalyst Pharmaceuticals (NASDAQ:CPRX) was downgraded by Zacks Research from a “strong-buy” rating to a “hold” rating in a note issued to investors on Monday,Zacks.com reports.

A number of other analysts have also commented on CPRX. Stephens set a $32.00 price objective on Catalyst Pharmaceuticals in a research report on Thursday, May 7th. Oppenheimer lowered Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 7th. Wall Street Zen lowered Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Cantor Fitzgerald upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Friday, March 27th. Finally, Citigroup lowered Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $35.00 to $31.50 in a research report on Friday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, Catalyst Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $32.17.

Catalyst Pharmaceuticals Stock Down 0.1%

Shares of CPRX stock opened at $31.21 on Monday. The stock has a 50-day moving average price of $26.42 and a 200 day moving average price of $24.50. The firm has a market cap of $3.82 billion, a price-to-earnings ratio of 17.94, a PEG ratio of 0.91 and a beta of 0.72. Catalyst Pharmaceuticals has a 12 month low of $19.05 and a 12 month high of $32.56.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

Several institutional investors have recently modified their holdings of CPRX. Rothschild Investment LLC lifted its holdings in shares of Catalyst Pharmaceuticals by 1,085.7% during the 3rd quarter. Rothschild Investment LLC now owns 1,660 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 1,520 shares in the last quarter. Advisory Services Network LLC bought a new position in shares of Catalyst Pharmaceuticals during the 3rd quarter valued at about $39,000. Quarry LP bought a new stake in Catalyst Pharmaceuticals in the 3rd quarter valued at approximately $40,000. Clearstead Advisors LLC lifted its stake in Catalyst Pharmaceuticals by 192.9% in the 4th quarter. Clearstead Advisors LLC now owns 1,772 shares of the biopharmaceutical company’s stock valued at $41,000 after acquiring an additional 1,167 shares in the last quarter. Finally, Smartleaf Asset Management LLC lifted its stake in Catalyst Pharmaceuticals by 55.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock valued at $41,000 after acquiring an additional 630 shares in the last quarter. Institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).